Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BTMD biote	$4.02 -3.6%	$3.95	$3.04 ▼ $8.10	$219.93M	1.21	167,291 shs	88,157 shs
GANX Gain Therapeutics	$1.59 -1.6%	$1.80	$0.89 ▼ $3.19	$47.66M	0.12	298,964 shs	209,764 shs
LRMR Larimar Therapeutics	$3.21 -3.3%	$2.66	$1.61 ▼ $9.97	$205.53M	0.86	844,742 shs	480,386 shs
MDWD MediWound	$20.46 +2.0%	$20.25	$14.14 ▼ $22.51	$221.13M	0.32	63,992 shs	77,898 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTMD biote	0.00%	-1.47%	+0.75%	+21.82%	-51.27%
GANX Gain Therapeutics	0.00%	-8.38%	-11.45%	-11.94%	+24.80%
LRMR Larimar Therapeutics	0.00%	-5.03%	+17.15%	+68.50%	-68.19%
MDWD MediWound	0.00%	+2.15%	+5.30%	+19.65%	+0.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BTMD biote	2.5948 of 5 stars	3.5	2.0	0.0	3.3	1.3
GANX Gain Therapeutics	2.3296 of 5 stars	3.6	3.0	2.6	0.0	0.6
LRMR Larimar Therapeutics	2.0048 of 5 stars	3.6	2.0	2.2	1.7	0.0
MDWD MediWound	1.6397 of 5 stars	3.5	1.0	1.6	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BTMD biote	3.00	Buy	$8.00	99.00% Upside
GANX Gain Therapeutics	3.17	Buy	$8.20	417.35% Upside
LRMR Larimar Therapeutics	3.11	Buy	$18.50	476.32% Upside
MDWD MediWound	3.00	Buy	$32.25	57.62% Upside

Current Analyst Ratings Breakdown

Latest GANX, MDWD, BTMD, and LRMR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/3/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/24/2025	LRMR Larimar Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
6/24/2025	LRMR Larimar Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $15.00
6/24/2025	LRMR Larimar Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$26.00
6/2/2025	MDWD MediWound	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$34.00
5/22/2025	MDWD MediWound	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$25.00 ➝ $31.00
5/19/2025	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/2/2025	MDWD MediWound	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$25.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BTMD biote	$197.19M	1.12	$0.77 per share	5.25	($2.78) per share	-1.45
GANX Gain Therapeutics	$50K	953.22	N/A	N/A	$0.28 per share	5.66
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$2.69 per share	N/A
MDWD MediWound	$20.22M	10.94	N/A	N/A	$2.89 per share	7.08

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BTMD biote	$3.16M	$0.61	6.59	7.44	N/A	10.93%	-19.44%	20.12%	8/6/2025 (Estimated)
GANX Gain Therapeutics	-$20.41M	-$0.86	N/A	N/A	N/A	N/A	-247.55%	-146.06%	8/6/2025 (Estimated)
LRMR Larimar Therapeutics	-$80.60M	-$1.49	N/A	N/A	N/A	N/A	-52.48%	-46.08%	8/6/2025 (Estimated)
MDWD MediWound	-$30.22M	-$2.09	N/A	N/A	N/A	-110.45%	-74.12%	-30.92%	8/13/2025 (Estimated)

Latest GANX, MDWD, BTMD, and LRMR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	BTMD biote	$0.06	N/A	N/A	N/A	$49.52 million	N/A
8/14/2025	Q2 2025	GANX Gain Therapeutics	-$0.17	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	MDWD MediWound	-$0.55	N/A	N/A	N/A	$5.68 million	N/A
8/6/2025	Q2 2025	LRMR Larimar Therapeutics	-$0.4877	N/A	N/A	N/A	N/A	N/A
5/21/2025	Q1 2025	MDWD MediWound	-$0.65	-$0.07	+$0.58	-$0.07	$5.20 million	$3.96 million
5/14/2025	Q1 2025	GANX Gain Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.03 million	N/A
5/7/2025	Q1 2025	BTMD biote	$0.06	$0.08	+$0.02	$0.37	$47.25 million	$48.99 million
4/30/2025	Q1 2025	LRMR Larimar Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BTMD biote	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
MDWD MediWound	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BTMD biote	N/A	1.42	1.14
GANX Gain Therapeutics	0.05	2.22	2.22
LRMR Larimar Therapeutics	N/A	7.48	7.48
MDWD MediWound	N/A	2.15	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BTMD biote	21.68%
GANX Gain Therapeutics	11.97%
LRMR Larimar Therapeutics	91.92%
MDWD MediWound	46.83%

Insider Ownership

Company	Insider Ownership
BTMD biote	24.00%
GANX Gain Therapeutics	7.18%
LRMR Larimar Therapeutics	4.50%
MDWD MediWound	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BTMD biote	194	54.71 million	41.58 million	Not Optionable
GANX Gain Therapeutics	20	30.07 million	27.91 million	Optionable
LRMR Larimar Therapeutics	30	64.03 million	61.15 million	Optionable
MDWD MediWound	80	10.81 million	9.81 million	Optionable

GANX, MDWD, BTMD, and LRMR Headlines

Recent News About These Companies

MediWound (NASDAQ:MDWD) Lowered to "Sell" Rating by Wall Street Zen

July 19 at 2:07 AM | marketbeat.com

MediWound (NASDAQ:MDWD) Stock Price Passes Above 50 Day Moving Average - Here's Why

July 15, 2025 | marketbeat.com

MediWound Ltd. (NASDAQ:MDWD) is definitely on the radar of institutional investors who own 42% of the company

July 7, 2025 | finance.yahoo.com

MediWound Ltd. (NASDAQ:MDWD) Given Average Rating of "Buy" by Analysts

June 27, 2025 | marketbeat.com

MediWound Ltd. (MDWD) latest stock news and headlines - Yahoo Finance

June 26, 2025 | sg.finance.yahoo.com

MediWound (NASDAQ:MDWD) Shares Pass Above Fifty Day Moving Average - Time to Sell?

June 25, 2025 | marketbeat.com

Companies Like MediWound (NASDAQ:MDWD) Are In A Position To Invest In Growth

June 2, 2025 | finance.yahoo.com

MediWound’s Q1 2025: Strategic Progress Amid Financial Challenges

May 21, 2025 | tipranks.com

MediWound (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | msn.com

MediWound Ltd. (MDWD) Q1 2025 Earnings Call Transcript

May 21, 2025 | seekingalpha.com

MediWound (MDWD) Reports Q1 Loss, Misses Revenue Estimates

May 21, 2025 | zacks.com

MediWound Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 21, 2025 | globenewswire.com

MediWound Q1 2025 Earnings Preview

May 20, 2025 | msn.com

MediWound Ltd.: Undervalued High-Growth Potential

May 16, 2025 | seekingalpha.com

MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers

May 13, 2025 | globenewswire.com

MediWound to Report First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences

April 28, 2025 | globenewswire.com

Those who invested in MediWound (NASDAQ:MDWD) five years ago are up 30%

April 17, 2025 | finance.yahoo.com

MediWound reports Q4 EPS (36c), consensus (61c)

March 20, 2025 | markets.businessinsider.com

MediWound files $125M mixed securities shelf

March 20, 2025 | markets.businessinsider.com

Loss-Making MediWound Ltd. (NASDAQ:MDWD) Expected To Breakeven In The Medium-Term

March 20, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GANX, MDWD, BTMD, and LRMR Company Descriptions

biote NASDAQ:BTMD

$4.02 -0.15 (-3.60%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$4.02 0.00 (0.00%)

As of 07/18/2025 06:03 PM Eastern

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.

Gain Therapeutics NASDAQ:GANX

$1.58 -0.03 (-1.55%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$1.57 -0.01 (-0.95%)

As of 07/18/2025 07:59 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Larimar Therapeutics NASDAQ:LRMR

$3.21 -0.11 (-3.31%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$3.22 +0.01 (+0.31%)

As of 07/18/2025 06:17 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

MediWound NASDAQ:MDWD

$20.46 +0.41 (+2.04%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$20.45 -0.01 (-0.05%)

As of 07/18/2025 04:04 PM Eastern

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time